Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MABTOX

Financiado

Cerrado

Generation and Evaluation of Next generation Antibody Toxin Conjugates for...

Generation and Evaluation of Next generation Antibody Toxin Conjugates for Cancer Therapy Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in comparison to standard small molecule chemotherapy. Most recently, the coupling of cellular... ver más

31/12/2015

NBE

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

NBETHERAPEUTICS AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-12-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

NBE

0.00€ | Lider

BIOMEDAL

N.D. | Participante

CHARLES RIVER DISCOVERY RESE...

N.D. | Participante

Proyectos interesantes

Syndivia

Medical Technol...

Pharmaceutical...

71K€ Cerrado

DESARROLLO DE INMUNOTERAPIAS CONTRA EL CÁNCER...

Medical Technol...

Pharmaceutical...

676K€ Cerrado

DESARROLLO Y OPTIMIZACIÓN DEL PROCESO DE SÍNT...

Medical Technol...

Chemical Engine...

759K€ Cerrado

MirrorBody

Medical Technol...

Biotechnology

196K€ Cerrado

MAGICBULLET

Medical Technol...

Chemical Engine...

4M€ Cerrado

ADC

Medical Technol...

Biotechnology

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

NBETHERAPEUTICS AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in comparison to standard small molecule chemotherapy. Most recently, the coupling of cellular toxins to therapeutic antibodies has demonstrated an even greater efficacy in the therapy of cancer and the first, highly potent antibody drug conjugate (ADC), Adcetris®, was FDA approved in August 2011. All ADCs currently in clinical development are generated by chemical conjugation of small molecule toxins to antibodies. This is an inefficient process, as site and ratio of toxin coupling cannot be controlled. In addition, the chemical conjugation involves chemical modification of potentially functional parts of the antibody. This can have negative effects on stability, specificity, CMC properties and the overall structure of the antibody. All this renders ADC manufacturing highly challenging, complicates regulatory procedures, and adds to development time and costs. The SME consortium has complementary proprietary technologies and proposes to leverage this complementary expertise and know-how for defining novel processes of enzymatically conjugating small molecule toxins to antibodies that allow full control about toxin coupling site and ratio. Due to the high selectivity of enzymatic conjugation and physiologic conjugation conditions, it is expected that more homogeneous ADCs are generated with better CMC properties, higher potency, and at lower cost-of-goods in manufacturing. The consortium members believe that this represents a disruptive technology that will be highly competitive to traditional chemical conjugation, currently dominated by U.S.-based ADC technology companies Seattle Genetics and Immunogen. In addition to novel composition-of-matter IP, important novel know-how for ADC development will be created. Most importantly, better quality and potency of these next-generation ADCs will eventually benefit cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores